Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 2 , Pages 181-192 , April 2009

Genetics of congenital adrenal hyperplasia

  • Nils Krone, MD (Wellcome Trust Clinician Scientist Fellow)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 121 414 2540; Fax: +44 121 415 8712.
    • ,
  • Wiebke Arlt, MD, DSc, FRCP (Professor of Medicine, MRC Senior Clinical Fellow)

References 

  1. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocrine Reviews. 2000;21:245–291
  2. Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet. 2005;365:2125–2136
  3. Ogilvie CM, Crouch NS, Rumsby G, et al. Congenital adrenal hyperplasia in adults: a review of medical, surgical and psychological issues. Clinical Endocrinology. 2006;64:2–11
  4. Arlt W, Krone N. Adult consequences of congenital adrenal hyperplasia. Hormone Research. 2007;68:158–164
  5. Krone N, Dhir V, Ivison HE, et al. Congenital adrenal hyperplasia and P450 oxidoreductase deficiency. Clinical Endocrinology. 2007;66:162–172
  6. Thilen A, Nordenstrom A, Hagenfeldt L, et al. Benefits of neonatal screening for congenital adrenal hyperplasia (21-hydroxylase deficiency) in Sweden. Pediatrics. 1998;101:E11
  7. Therrell BL, Berenbaum SA, Manter-Kapanke V, et al. Results of screening 1.9 million Texas newborns for 21-hydroxylase- deficient congenital adrenal hyperplasia. Pediatrics. 1998;101:583–590
  8. Van der Kamp HJ, Noordam K, Elvers B, et al. Newborn screening for congenital adrenal hyperplasia in the Netherlands. Pediatrics. 2001;108:1320–1324
  9. Pang S, Murphey W, Levine LS, et al. A pilot newborn screening for congenital adrenal hyperplasia in Alaska. The Journal of Clinical Endocrinology and Metabolism. 1982;55:413–420
  10. Pang SY, Wallace MA, Hofman L, et al. Worldwide experience in newborn screening for classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics. 1988;81:866–874
  11. Mikami A, Fukushi M, Oda H, et al. Newborn screening for congenital adrenal hyperplasia in Sapporo city: sixteen years experience. The Southeast Asian Journal of Tropical Medicine and Public Health. 1999;30(Suppl. 2):100–102
  12. Lee HH, Kuo JM, Chao HT, et al. Carrier analysis and prenatal diagnosis of congenital adrenal hyperplasia caused by 21-hydroxylase deficiency in Chinese. The Journal of Clinical Endocrinology and Metabolism. 2000;85:597–600
  13. Speiser PW, White PC. Congenital adrenal hyperplasia. The New England Journal of Medicine. 2003;349:776–788
  14. Payne AH, Hales DB. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocrine Reviews. 2004;25:947–970
  15. Miller WL. Minireview: regulation of steroidogenesis by electron transfer. Endocrinology. 2005;146:2544–2550
  16. White PC, New MI, Dupont B. Structure of human steroid 21-hydroxylase genes. Proceedings of the National Academy of Sciences of the United States of America. 1986;83:5111–5115
  17. Higashi Y, Yoshioka H, Yamane M, et al. Complete nucleotide sequence of two steroid 21-hydroxylase genes tandemly arranged in human chromosome: a pseudogene and a genuine gene. Proceedings of the National Academy of Sciences of the United States of America. 1986;83:2841–2845
  18. White PC, Grossberger D, Onufer BJ, et al. Two genes encoding steroid 21-hydroxylase are located near the genes encoding the fourth component of complement in man. Proceedings of the National Academy of Sciences of the United States of America. 1985;82:1089–1093
  19. Carroll MC, Campbell RD, Porter RR. Mapping of steroid 21-hydroxylase genes adjacent to complement component C4 genes in HLA, the major histocompatibility complex in man. Proceedings of the National Academy of Sciences of the United States of America. 1985;82:521–525
  20. Yang Z, Mendoza AR, Welch TR, et al. Modular variations of the human major histocompatibility complex class III genes for serine/threonine kinase RP, complement component C4, steroid 21-hydroxylase CYP21, and tenascin TNX (the RCCX module). A mechanism for gene deletions and disease associations. The Journal of Biological Chemistry. 1999;274:12147–12156
  21. Blanchong CA, Zhou B, Rupert KL, et al. Deficiencies of human complement component C4A and C4B and heterozygosity in length variants of RP-C4-CYP21-TNX (RCCX) modules in caucasians. The load of RCCX genetic diversity on major histocompatibility complex-associated disease. The Journal of Experimental Medicine. 2000;191:2183–2196
  22. Koppens PF, Hoogenboezem T, Degenhart HJ. Carriership of a defective tenascin-X gene in steroid 21-hydroxylase deficiency patients: TNXB -TNXA hybrids in apparent large-scale gene conversions. Human Molecular Genetics. 2002;11:2581–2590
  23. Speiser PW, Dupont J, Zhu D, et al. Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. The Journal of Clinical Investigation. 1992;90:584–595
  24. Wedell A, Thilen A, Ritzen EM, et al. Mutational spectrum of the steroid 21-hydroxylase gene in Sweden: implications for genetic diagnosis and association with disease manifestation. The Journal of Clinical Endocrinology and Metabolism. 1994;78:1145–1152
  25. Jaaskelainen J, Levo A, Voutilainen R, et al. Population-wide evaluation of disease manifestation in relation to molecular genotype in steroid 21-hydroxylase (CYP21) deficiency: good correlation in a well defined population. The Journal of Clinical Endocrinology and Metabolism. 1997;82:3293–3297
  26. Krone N, Braun A, Roscher AA, et al. Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany. The Journal of Clinical Endocrinology and Metabolism. 2000;85:1059–1065
  27. Stikkelbroeck NM, Hoefsloot LH, de Wijs IJ, et al. CYP21 gene mutation analysis in 198 patients with 21-hydroxylase deficiency in the Netherlands: six novel mutations and a specific cluster of four mutations. The Journal of Clinical Endocrinology and Metabolism. 2003;88:3852–3859
  28. Kharrat M, Tardy V, M'Rad R, et al. Molecular genetic analysis of Tunisian patients with a classic form of 21-hydroxylase deficiency: identification of four novel mutations and high prevalence of Q318X mutation. The Journal of Clinical Endocrinology and Metabolism. 2004;89:368–374
  29. Wilson RC, Nimkarn S, Dumic M, et al. Ethnic-specific distribution of mutations in 716 patients with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Molecular Genetics and Metabolism. 2007;90:414–421
  30. Wilson RC, Mercado AB, Cheng KC, et al. Steroid 21-hydroxylase deficiency: genotype may not predict phenotype. The Journal of Clinical Endocrinology and Metabolism. 1995;80:2322–2329
  31. Bachega TA, Billerbeck AE, Madureira G, et al. Molecular genotyping in Brazilian patients with the classical and nonclassical forms of 21-hydroxylase deficiency. The Journal of Clinical Endocrinology and Metabolism. 1998;83:4416–4419
  32. Rocha RO, Billerbeck AE, Pinto EM, et al. The degree of external genitalia virilization in girls with 21-hydroxylase deficiency appears to be influenced by the CAG repeats in the androgen receptor gene. Clinical Endocrinology. 2008;68:226–232
  33. Gomes LG, Huang N, Agrawal V, et al. The Common P450 oxidoreductase variant A503V is not a modifier gene for 21-hydroxylase deficiency. The Journal of Clinical Endocrinology and Metabolism. 2008;93:2913–2916
  34. Huang N, Agrawal V, Giacomini KM, et al. Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proceedings of the National Academy of Sciences of the United States of America. 2008;105:1733–1738
  35. White PC, Vitek A, Dupont B, et al. Characterization of frequent deletions causing steroid 21-hydroxylase deficiency. Proceedings of the National Academy of Sciences of the United States of America. 1988;85:4436–4440
  36. Morel Y, Andre J, Uring-Lambert B, et al. Rearrangements and point mutations of P450c21 genes are distinguished by five restriction endonuclease haplotypes identified by a new probing strategy in 57 families with congenital adrenal hyperplasia. The Journal of Clinical Investigation. 1989;83:527–536
  37. Krone N, Roscher AA, Schwarz HP, et al. Comprehensive analytical strategy for mutation screening in 21- hydroxylase deficiency. Clinical Chemistry. 1998;44:2075–2082
  38. Olney RC, Mougey EB, Wang J, et al. Using real-time, quantitative PCR for rapid genotyping of the steroid 21-hydroxylase gene in a north Florida population. The Journal of Clinical Endocrinology and Metabolism. 2002;87:735–741
  39. Parajes S, Quinterio C, Dominguez F, et al. A simple and robust quantitative PCR assay to determine CYP21A2 gene dose in the diagnosis of 21-hydroxylase deficiency. Clinical Chemistry. 2007;53:1577–1584
  40. Lee H-H, Lee Y-J, Chan P, et al. Use of PCR-based amplification analysis as a substitute for the southern blot method for CYP21 deletion detection in congenital adrenal hyperplasia. Clinical Chemistry. 2004;50:1074–1076
  41. Keen-Kim D, Redman JB, Alanes RU, et al. Validation and clinical application of a locus-specific polymerase chain reaction- and minisequencing-based assay for congenital adrenal hyperplasia (21-hydroxylase deficiency). The Journal of Molecular Diagnostics. 2005;7:236–246
  42. Koppens PF, Degenhart HJ. PCR-based detection of CYP21 deletions. Clinical Chemistry. 2003;49:1555–1556author reply 1556–1557
  43. Schouten JP, McElgunn CJ, Waaijer R, et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Research. 2002;30:e57
  44. l'Allemand D, Tardy V, Gruters A, et al. How a patient homozygous for a 30-kb deletion of the C4-CYP 21 genomic region can have a nonclassic form of 21-hydroxylase deficiency. The Journal of Clinical Endocrinology and Metabolism. 2000;85:4562–4567
  45. Wedell A, Luthman H. Steroid 21-hydroxylase deficiency: two additional mutations in salt- wasting disease and rapid screening of disease-causing mutations. Human Molecular Genetics. 1993;2:499–504
  46. Day DJ, Speiser PW, White PC, et al. Detection of steroid 21-hydroxylase alleles using gene-specific PCR and a multiplexed ligation detection reaction. Genomics. 1995;29:152–162
  47. Krone N, Braun A, Weinert S, et al. Multiplex minisequencing of the 21-hydroxylase gene as a rapid strategy to confirm congenital adrenal hyperplasia. Clinical Chemistry. 2002;48:818–825
  48. Ezquieta B, Varela JM, Jariego C, et al. Nonisotopic detection of point mutations in CYP21B gene in steroid 21- hydroxylase deficiency. Clinical Chemistry. 1996;42:1108–1110
  49. Speiser PW, White PC, Dupont J, et al. Prenatal diagnosis of congenital adrenal hyperplasia due to 21- hydroxylase deficiency by allele-specific hybridization and Southern blot. Human Genetics. 1994;93:424–428
  50. Rosler A, Leiberman E, Cohen T. High frequency of congenital adrenal hyperplasia (classic 11 beta-hydroxylase deficiency) among Jews from Morocco. American Journal of Medical Genetics. 1992;42:827–834
  51. Joehrer K, Geley S, Strasser-Wozak EM, et al. CYP11B1 mutations causing non-classic adrenal hyperplasia due to 11 beta-hydroxylase deficiency. Human Molecular Genetics. 1997;6:1829–1834
  52. Mornet E, Dupont J, Vitek A, et al. Characterization of two genes encoding human steroid 11 beta- hydroxylase (P-450(11) beta). The Journal of Biological Chemistry. 1989;264:20961–20967
  53. White PC, Dupont J, New MI, et al. A mutation in CYP11B1 (Arg-448–His) associated with steroid 11 beta-hydroxylase deficiency in Jews of Moroccan origin. The Journal of Clinical Investigation. 1991;87:1664–1667
  54. Curnow KM, Slutsker L, Vitek J, et al. Mutations in the CYP11B1 gene causing congenital adrenal hyperplasia and hypertension cluster in exons 6, 7, and 8. Proceedings of the National Academy of Sciences of the United States of America. 1993;90:4552–4556
  55. Helmberg A, Ausserer B, Kofler R. Frame shift by insertion of 2 basepairs in codon 394 of CYP11B1 causes congenital adrenal hyperplasia due to steroid 11 beta-hydroxylase deficiency. The Journal of Clinical Endocrinology and Metabolism. 1992;75:1278–1281
  56. Naiki Y, Kawamoto T, Mitsuuchi Y, et al. A nonsense mutation (TGG [Trp116]→TAG [Stop]) in CYP11B1 causes steroid 11 beta-hydroxylase deficiency. The Journal of Clinical Endocrinology and Metabolism. 1993;77:1677–1682
  57. Skinner CA, Rumsby G. Steroid 11 beta-hydroxylase deficiency caused by a five base pair duplication in the CYP11B1 gene. Human Molecular Genetics. 1994;3:377–378
  58. Yang LX, Toda K, Miyahara K, et al. Classic steroid 11 beta-hydroxylase deficiency caused by a C– >G transversion in exon 7 of CYP11B1. Biochemical and Biophysical Research Communications. 1995;216:723–728
  59. Nakagawa Y, Yamada M, Ogawa H, et al. Missense mutation in CYP11B1 (CGA[Arg-384]–>GGA[Gly]) causes steroid 11 beta-hydroxylase deficiency. European Journal of Endocrinology. 1995;132:286–289
  60. Geley S, Kapelari K, Johrer K, et al. CYP11B1 mutations causing congenital adrenal hyperplasia due to 11 beta- hydroxylase deficiency. The Journal of Clinical Endocrinology and Metabolism. 1996;81:2896–2901
  61. Merke DP, Tajima T, Chhabra A, et al. Novel CYP11B1 Mutations in congenital adrenal hyperplasia due to steroid 11{beta}-hydroxylase deficiency. The Journal of Clinical Endocrinology and Metabolism. 1998;83:270–273
  62. Zhu YS, Cordero JJ, Can S, et al. Mutations in CYP11B1 gene: phenotype-genotype correlations. American Journal of Medical Genetics. 2003;122A:193–200
  63. Krone N, Riepe FG, Gotze D, et al. Congenital adrenal hyperplasia due to 11-hydroxylase deficiency: functional characterization of two novel point mutations and a three-base pair deletion in the CYP11B1 gene. The Journal of Clinical Endocrinology and Metabolism. 2005;90:3724–3730
  64. Krone N, Grischuk Y, Muller M, et al. Analyzing the functional and structural consequences of two point mutations (P94L and A368D) in the CYP11B1 gene causing congenital adrenal hyperplasia resulting from 11-hydroxylase deficiency. The Journal of Clinical Endocrinology and Metabolism. 2006;91:2682–2688
  65. Hampf M, Dao NT, Hoan NT, et al. Unequal crossing-over between aldosterone synthase and 11beta-hydroxylase genes causes congenital adrenal hyperplasia. The Journal of Clinical Endocrinology and Metabolism. 2001;86:4445–4452
  66. Lifton RP, Dluhy RG, Powers M, et al. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature. 1992;355:262–265
  67. Auchus RJ. The genetics, pathophysiology, and management of human deficiencies of P450c17. Endocrinology and Metabolism Clinics of North America. 2001;30:101–119vii
  68. Geller DH, Auchus RJ, Mendonca BB, et al. The genetic and functional basis of isolated 17,20/lyase deficiency. Nature Genetics. 1997;17:201–205
  69. Sherbet DP, Tiosano D, Kwist KM, et al. CYP17 mutation E305G causes isolated 17,20-lyase deficiency by selectively altering substrate binding. The Journal of Biological Chemistry. 2003;278:48563–48569
  70. Auchus RJ, Lee TC, Miller WL. Cytochrome b5 augments the 17,20-lyase activity of human P450c17 without direct electron transfer. The Journal of Biological Chemistry. 1998;273:3158–3165
  71. Geller DH, Auchus RJ, Miller WL. P450c17 mutations R347H and R358Q selectively disrupt 17,20-lyase activity by disrupting interactions with P450 oxidoreductase and cytochrome b5. Molecular Endocrinology. 1999;13:167–175
  72. Costa-Santos M, Kater CE, Auchus RJ. Two Prevalent CYP17 mutations and genotype-phenotype correlations in 24 Brazilian patients with 17-hydroxylase deficiency. The Journal of Clinical Endocrinology and Metabolism. 2004;89:49–60
  73. Imai T, Yanase T, Waterman MR, et al. Canadian mennonites and individuals residing in the Friesland region of the Netherlands share the same molecular basis of 17 alpha-hydroxylase deficiency. Human Genetics. 1992;89:95–96
  74. Miura K, Yasuda K, Yanase T, et al. Mutation of cytochrome P-45017 alpha gene (CYP17) in a Japanese patient previously reported as having glucocorticoid-responsive hyperaldosteronism: with a review of Japanese patients with mutations of CYP17. The Journal of Clinical Endocrinology and Metabolism. 1996;81:3797–3801
  75. Fardella CE, Zhang LH, Mahachoklertwattana P, et al. Deletion of amino acids Asp487-Ser488-Phe489 in human cytochrome P450c17 causes severe 17 alpha-hydroxylase deficiency. The Journal of Clinical Endocrinology and Metabolism. 1993;77:489–493
  76. Lam CW, Arlt W, Chan CK, et al. Mutation of Proline 409 to Arginine in the meander region of cytochrome P450c17 causes severe 17a-hydroxylase deficiency. Molecular Genetics and Metabolism. 2001;72:254–259
  77. Qiao J, Hu RM, Peng YD, et al. A complex heterozygous mutation of His373Leu and Asp487-Ser488-Phe489 deletion in human cytochrome P450c17 causes 17alpha-hydroxylase/17,20-lyase deficiency in three Chinese sisters. Molecular and Cellular Endocrinology. 2003;201:189–195
  78. Tiosano D, Knopf C, Koren I, et al. Metabolic evidence for impaired 17alpha-hydroxylase activity in a kindred bearing the E305G mutation for isolate 17,20-lyase activity. European Journal of Endocrinology. 2008;158:385–392
  79. Hershkovitz E, Parvari R, Wudy SA, et al. Homozygous mutation G539R in the gene for P450 oxidoreductase in a family previously diagnosed as having 17,20-lyase deficiency. The Journal of Clinical Endocrinology and Metabolism. 2008;93:3584–3588
  80. Simard J, Ricketts M-L, Gingras S, et al. Molecular biology of the 3{beta}-hydroxysteroid dehydrogenase/{delta}5-{delta}4 isomerase gene family. Endocrine Reviews. 2005;26:525–582
  81. Chang YT, Kappy MS, Iwamoto K, et al. Mutations in the type II 3 beta-hydroxysteroid dehydrogenase gene in a patient with classic salt-wasting 3 beta-hydroxysteroid dehydrogenase deficiency congenital adrenal hyperplasia. Pediatric Research. 1993;34:698–700
  82. Peterson RE, Imperato-McGinley J, Gautier T, et al. Male pseudohermaphroditism due to multiple defects in steroid-biosynthetic microsomal mixed-function oxidases. A new variant of congenital adrenal hyperplasia. The New England Journal of Medicine. 1985;313:1182–1191
  83. Fluck CE, Tajima T, Pandey AV, et al. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without antley-bixler syndrome. Nature Genetics. 2004;36:228–230
  84. Arlt W, Walker EA, Draper N, et al. Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet. 2004;363:2128–2135
  85. Scott RR, Gomes LG, Huang N, et al. Apparent manifesting heterozygosity in P450 oxidoreductase deficiency and its effect on coexisting 21-hydroxylase deficiency. The Journal of Clinical Endocrinology and Metabolism. 2007;92:2318–2322
  86. Huang N, Pandey AV, Agrawal V, et al. Diversity and function of mutations in p450 oxidoreductase in patients with antley-bixler syndrome and disordered steroidogenesis. American Journal of Human Genetics. 2005;76:729–749
  87. Adachi M, Tachibana K, Asakura Y, et al. Compound heterozygous mutations of cytochrome P450 oxidoreductase gene (POR) in two patients with antley-bixler syndrome. American Journal of Medical Genetics. 2004;128A:333–339
  88. Fukami M, Horikawa R, Nagai T, et al. Cytochrome P450 oxidoreductase gene mutations and antley-bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients. The Journal of Clinical Endocrinology and Metabolism. 2005;90:414–426
  89. Adachi M, Asakura Y, Matsuo M, et al. POR R457H is a global founder mutation causing antley-bixler syndrome with autosomal recessive trait. American Journal of Medical Genetics. Part A. 2006;140:633–635
  90. Fukami M, Hasegawa T, Horikawa R, et al. Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatric Research. 2006;59:276–280
  91. Shackleton C, Marcos J, Malunowicz EM, et al. Biochemical diagnosis of antley-bixler syndrome by steroid analysis. American Journal of Medical Genetics. 2004;128A:223–231
  92. Homma K, Hasegawa T, Nagai T, et al. Urine steroid hormone profile analysis in cytochrome P450 oxidoreductase deficiency: implication for the backdoor pathway to dihydrotestosterone. The Journal of Clinical Endocrinology and Metabolism. 2006;91:2643–2649

PII: S1521-690X(08)00144-9

doi: 10.1016/j.beem.2008.10.014

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 2 , Pages 181-192 , April 2009

Article Tools

* Image Usage & Resolution